New and Experimental HIV Drugs

New and Experimental HIV Drugs

(See also CCR5 and CXCR4 BlockersEntry Inhibitors; HIV Maturation Inhibitors; Integrase Inhibitors)  


General Information about HIV Medications

Antiretroviral Formulations.  Chart from AIDSinfo listing all available formulations of anti-HIV drugs approved by the Food and Drug Administration for use in the United States.  For each drug, there is a link to an associated fact sheet with information about that specific medication.  Also available in Spanish.
 
FDA-Approved Anti-HIV Medications.  Fact sheet from AIDSinfo with a list of medications used to treat HIV infection, including generic and brand names and date approved by the Food and Drug Administration for use in the United States.   For each drug, there is a link to an associated fact sheet with information about that specific medication.  Also available in Spanish.


Background Information about New and Experimental Antiviral Drugs

Nucleoside analog reverse transcriptase inhibitors in development.  Fact sheet from AIDS InfoNet.  Also available in Spanish.

Non-nucleoside reverse transcriptase inhibitors in development. Fact sheet from AIDS InfoNet. Also available in Spanish.

Protease inibitors in development. Fact sheet from AIDS InfoNet.  Also available in Spanish.

Attachment and fusion inhibitors in development.  Fact sheet from InfoNet.  Also available in Spanish.

Other antiretroviral drugs in development. Fact sheet from AIDS InfoNet.  Also available in Spanish.


Information about Particular Experimental Drugs 

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

GS 7340. Fact sheet from aidsmeds.com.

Racivir (RCV).  Fact sheet from aidsmeds.com.  Also available in Spanish.

Amdoxovir (DAPD).  Fact sheet from aidsmeds.com.  Also available in Spanish.

Apricitabine.  Fact sheet from aidsmeds.com. 

Elvucitabine.  Fact sheet from aidsmeds.com.  Also available in Spanish.


Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

GSK-2248761. Fact sheet from aidsmeds.com.

Lersivirine. Fact sheet from aidsmeds.com.


Entry Inhibitors (including Fusion Inhibitors)

Entry inhibitors (including fusion inhibitors):  What are they?  Fact sheet from aidsmeds.com.  Also available in Spanish.

Cenicriviroc. Fact sheet from aidsmeds.com.

Vicriviroc (SCH-D).  Fact sheet from aidsmeds.com.  Also available in Spanish.

PRO 140. Fact sheet from aidsmeds.com. Also available in Spanish.

Ibalizumab. Fact sheet from aidsmeds.com.  Also available in Spanish.


Integrase Inhibitors

Integrase inhibitors:  What are they?  Fact sheet from aidsmeds.com.  Also available in Spanish.

Elvitegravir. Fact sheet from aidsmeds.com. Also available in Spanish.

GSK-572. Fact sheet from aidsmeds.com.


Maturation Inhibitors

Bevirimat.  Fact sheet from aidsmeds.com.  Also available in Spanish.


Drug Level Boosters

Pharmacokinetic enhancers: What are they?  Fact sheet from aidsmeds.com.

Cobicistat.  Fact sheet from aidsmeds.com. 

SPI-452.  Fact sheet from aidsmeds.com.

Combination ARV Pills

Quad. Fact sheet from aidsmeds.com.


Immune-Based Therapies

Immune-Based Therapies. Fact sheet from aidsmeds.com.

Immunitin (HE2000, alpha-epibromide).  Fact sheet from aidsmeds.com.  Also available in Spanish.

Proleukin (aldesleukin, Interleukin-2, IL-2).  Fact sheet from aidsmeds.com.  Also available in Spanish.

Remune (HIV-1 Immunogen, Salk vaccine).  Fact sheet from aidsmeds.com.  Also available in Spanish.

BAY 50-4798.  Fact sheet from aidsmeds.com.  Also available in Spanish.

IR103.  Fact sheet from aidsmeds.com.  Also available in Spanish.

Aralen. Fact sheet from aidsmeds.com.

Plaquenil. Fact sheet from aidsmeds.com.

Lexgenleucel-T. Fact sheet from aidsmeds.com.

IL-7. Fact sheet from aidsmeds.com.

SB-728-T. Fact sheet from aidsmeds.com.

DermaVir. Fact sheet from aidsmeds.com.

Vacc-4x. Fact sheet from aidsmeds.com.

Selected Recent Articles About New and Experimental Drugs

 

Researchers Identify Protein that Prevents HIV from Entering Cells. Article dated May 30, 2012 from hivandhepatitis.com.

Gilead Quad Tablet Gets FDA Committee Approval Nod. Article dated May 11, 2012 from aidsmeds.com.

Gene-Modified T Cells Persist for a Decade, Without Major Risks, in HIV Studies. Article dated May 3, 2012 from aidsmeds.com. 

Three Big HIV Days in May at the FDA. Article dated April 19, 2012 by aidsmeds.com.

CROI: The Long and Winding Road to a Cure for HIV. Article dated April 13, 2012 from hivandhepatitis.com.

Engineering CD8 Cells to Kill HIV in Tissues. Article dated April 13, 2012 from aidsmeds.com.

Toward a Cure: The Potential of Therapeutic Vaccines. Article dated April 10, 2012 from aidsmeds.com.

Novel HIV Integrase Inhibitor Dolutegravir Matches Raltegravir in Phase 3 Study. Article dated April 3, 2012 from hivandhepatitis.com.

Cannabinoids May Inhibit CD4 Cell Infection by CXCR4-tropic HIV. Article dated March 30, 2012 from hivandhepatitis.com.

Zinc Finger HIV Gene Therapy Moves Ahead. Article dated March 27, 2012 from hivandhepatitis.com.

Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?  Article dated March 21, 2012 from aidsmeds.com.

CROI: Vorinostat -- A First Step on the Road Towards a Cure for HIV. Article dated March 16, 2012 from hivandhepatitis.com.

GS-7340 Packs Greater HIV Punch, Potentially Better Safety, Versus Viread. Article dated March 15, 2012 from aidsmeds.com.

Elvitegravir Quad pill matches efavirenz and atazanavir combos. Article dated March 13, 2012 from aidsmap.com.

Quad Comparable to Norvir-Reyataz Regimen in Phase III Study. Article dated March 13, 2012 from aidsmeds.com.

4-in-1 Elvitegravir Quad Pill Matches Efavirenz and Atazanavir Combos. Article dated March 13, 2012 from hivandhepatitis.com.

Novel integrase inhibitor dolutegravir still potent at 96 weeks. Article dated March 9, 2012 from aidsmap.com.

Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells. Article dated March 9, 2012 from aidsmeds.com.

CROI: HIV Drug Development News from CROI 2012. Article dated March 9, 2012 from hivandhepatitis.com.

CROI: New Integrase Inhibitor Dolutegravir Still Potent and Well-Tolerated at 96 Weeks. Article dated March 9, 2012 from hivandhepatitis.com.

Gilead Quad Performance Comparable to Atripla in First-Time Treatment Takers. Article dated March 8, 2012 from aidsmeds.com.

Tenofovir pro-drug GS-7340 shows good safety and efficacy in short study. Article dated March 8, 2012 from aidsmap.com.

Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation. Article dated March 8, 2012 from hivandhepatitis.com.

Once-a-month HIV drug maintains good levels for prevention; few side-effects so far. Article dated March 7, 2012 from aidsmap.com.

ViiV’s Dolutegravir Continues to Show Well After 96 Weeks, Versus Sustiva, for First-Time Treatment. Article dated March 7, 2012 from aidsmeds.com.

Dolutegravir Expanded Access Begins, but Advocates Urge Caution. Article dated March 6, 2012 from hivandhepatitis.com.

Early Access Program for Integrase Inhibitor Dolutegravir Launched. Article dated March 5, 2012 from aidsmeds.com.

Possible Cure in Protein That Starves HIV of Needed Building Blocks. Article dated February 27, 2012 from aidsmeds.com.

Researchers Show How SAMHD1 Prevents HIV Replication in Macrophages. Article dated February 14, 2012 from hivandhepatitis.com.

Briefly: New all-in-one HIV drug, the Quad, goes before FDA. Article dated January/February 2012 from Positively Aware.

Briefly: Drug makers sign agreements on new fixed-dose combo pills. Article dated January/February 2012 from Positively Aware.

The Path to a Cure. Article dated January/February 2012 from Positively Aware.

Conference Update. See the section, "Complera and Atripla News." Article dated January/February 2012 from Positively Aware.

Gilead Starts Phase 2 Trial of Tenofovir Pro-drug GS-7340. Article dated January 31, 2011 from hivandhepatitis.com.

New Gilead GS 7340-Inclusive Fixed-Dose Combo Tablet Trial Announced. Article dated January 26, 2012 from aidsmeds.com.

Sangamo HIV Gene Therapy Trials: Until There's A Functional Cure, Treatment! Article dated January 19, 2012 from hivandhepatitis.com.

New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy. Article dated January 10, 2012 from aidsmeds.com.

Identification of Host Cell Proteins "Hijacked" by HIV Offers Clues to Potential Therapies. Article dated January 3, 2012 from hivandhepatitis.com.

HIV's 'Pathogenic Landscape' Research Identifies New Drug Targets. Article dated December 27, 2011 from aidsmeds.com.

Researchers Discover Protein "Key" that Allows HIV to Enter Host Cell Nucleus. Article dated December 21, 2011 from hivandhepatitis.com.

Novel P7 Inhibitor BIT225 Improves Hepatitis C Response, also Inhibits HIV.  Article dated December 16, 2011 from hivandhepatitis.com.

Animal Studies Suggest Anti-Reservoir Drugs May Help 'Functionally Cure' HIV. Article dated December 14, 2011 from aidsmeds.com.

Elvitegravir Continues to Look Good at 2 Years. Article dated December 14, 2011 from hivandhepatitis.com.

Cobicistat Booster Works as Well as Ritonavir at 48 Weeks. Article dated December 6, 2011 from hivandhepatitis.com.

Boosting Agent Cobicistat Comparable to Norvir in Phase III Study. Article dated December 5, 2011 from aidsmeds.com.

Briefly: New arrivals: Complera and Edurant. Article dated November/December 2011 from Positively Aware.

The Quad gets closer to approval. Article dated November/December 2011 from Positively Aware.

Novel Compound Dissolves HIV on Contact, also Kills Hepatitis C Virus. Article dated November 29, 2011 from hivandhepatitis.com.

Advances in CCR5 Gene Therapy Give New Hope for HIV Cure. Article dated November 29, 2011 from aidsmeds.com.

New Single-Tablet Regimen for HIV Treatment Under Development. Article dated November 18, 2011 from hivandhepatitis.com.

Complete One-Pill, Once-Daily Prezista-Based HIV Regimen Enters Development. Article dated November 16, 2011 from aidsmeds.com.

Gilead s HIV 'Quad' Tablet Now Before FDA for Approval Review. Article dated November 1, 2011 from aidsmeds.com.

Bristol-Myers Squibb and Gilead Will Develop Atazanavir/Cobicistat HIV Combination Pill. Article dated October 28, 2011 from hivandhepatitis.com.

Quad Single-Tablet HIV Regimen Submitted for FDA Approval. Article dated October 28, 2011 from hivandhepatitis.com.

Cobicistat-Boosted Reyataz Pill in the Works. Article dated October 27, 2011 from aidsmeds.com.

An HIV Drug Delivery Patch in the Pipeline. Article dated October 26, 2011 from aidsmeds.com.

EACS: Dolutegravir Twice-Daily is Most Effective for Treatment-Experienced HIV Patients. Article dated October 14, 2011 from hivandhepatitis.com.

Dolutegravir is potent but twice-daily works better for integrase-resistant. Article dated October 14, 2011 from aidsmap.com.

Gambling for a Cure for HIV. - Article dated October 11, 2011 from hivandhepatitis.com.

Cell-Penetrating Peptides Like HIV Tat Have Multiple Ways to Enter Cells. Article dated October 11, 2011 from hivandhepatitis.com.

ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV. Article dated October 7, 2011 from hivandhepatitis.com.

Briefly: Prezista to get new, non-Norvir booster. Article dated September/October 2011 from Positively Aware.

Briefly: Cenicriviroc begins Phase 2b trial. Article dated September/October 2011 from Positively Aware.

Conference Update From IAS 2011: Medication News. Article dated September/October 2011 from Positively Aware.

Cholesterol-depleted HIV Triggers Adaptive Immune Response.  Article dated September 30, 2011 from hivandhepatitis.com.

Tobira Recruiting for Trial of CCR2/CCR5 Entry Inhibitor Cenicriviroc.  Article dated September 30, 2011 from hivandhepatitis.com.

HIV Antibody Therapy Ibalizumab Inches Forward. Article dated September 27, 2011 from aidsmeds.com.

Gilead Quad Performed Similarly to Norvir/Reyataz/Truvada Regimen in Phase III Study. Article dated September 26, 2011 from aidsmeds.com.

Complera Counterpart Eviplera Recommended for European Approval. Article dated September 23, 2011 from aidsmeds.com.

Quad Pill Works as Well as Atazanavir Combo at 48 Weeks. Article dated September 23, 2011 from hivandhepatitis.com.

ICAAC: Cobicistat Matches Ritonavir as Booster, Studies Clarify Effects on Kidney Function. Article dated September 23, 2011 from hivandhepatitis.com.

Sangamo's Gene Therapy Continues to Show Well in Study. Article dated September 21, 2011 from aidsmeds.com. 

Gene therapy for HIV is “progress towards functional cure” say researchers. Article dated September 20, 2011 from aidsmap.com. 

ICAAC: Zinc Finger Gene Therapy Boosts CD4 Cells, May Lower HIV Viral Load. Article dated September 20, 2011 from hivandhepatitis.com.  

Federal HIV Treatment Guidelines Panel Releases Information on Rilpivirine (Edurant).  Article dated August 17, 2011 from hivandhepatitis.com.

HIV Used in Experimental Treatment to Cure Leukemia. Article dated September 14, 2011 from aidsmeds.com.

Fluorescent Cats and the Development of Gene-Based Therapies Against HIV. Article dated September 12, 2011 from aidsmeds.com.

Quad Pill Effectiveness Matches Atripla at 48 Weeks. Article dated August 17, 2011 from hivandhepatitis.com.

Gilead 'Quad' Performed Similarly to Atripla in Phase III Study. Article dated August 15, 2011 from aidsmeds.com.

DRACO: A Broad-Spectrum Therapy Against Multiple Viruses. Article dated August 12, 2011 from aidsmeds.com.

U.S. approval for new three-drug combination pill.  Article dated August 11, 2011 from aidsmap.com.

FDA Approves Complera, New Single-Pill Regimen for HIV.  Article dated August 10, 2011 from hivandhepatitis.com. 

New Three-in-One HIV Med Complera Approved.  Article dated August 10, 2011 from aidsmeds.com.

Engineered Virus Delivers 'Suicide Gene Therapy' to HIV-infected Cells. Article dated August 9, 2011 from hivandhepatitis.com.

Cobicistat Comparable to Norvir as HIV Boosting Agent. Article dated August 8, 2011 from aidsmeds.com.

Statins Greatly Reduce Risk of Death in HIV Cohort Study. Article dated August 5, 2011 from aidsmeds.com.

Experimental Pharmacoenhancer Cobicistat Matches Ritonavir as Booster. Article dated August 5, 2011 from hivandhepatitis.com.

Pipeline Report Shows Good Prospects for People with HIV, HCV, and TB. Article dated July 29, 2011 from hivandhepatitis.com.

IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated. Article dated July 26, 2011 from hivandhepatitis.com.

Once-daily elvitegravir matches raltegravir. Article dated July 21, 2011 from aidsmap.com.

IAS 2011: New NNRTI Lersivirine Looks Good in Phase 2 Study.  Article dated July 21, 2011 from hivandhepatitis.com.

Elvitegravir Proving Comparable to Isentress in HIV Treatment Veterans. Article dated July 20, 2011 from aidsmeds.com.

HIV Integrase Inhibitor Dolutegravir Showing Well in First-Time Treatment Takers. Article dated July 19, 2011 from aidsmeds.com.

Non-Nuke Lersivirine Promising in First-Time Treatment Takers. Article dated July 19, 2011 from aidsmeds.com.

Medicines Patent Pool Licenses First HIV and HBV Drugs.  Article dated July 18, 2011 from hivandhepatitis.com.

Gilead and Tibotec To Develop New Combo Pill.  Article dated July 5, 2011 from hivandhepatitis.com.

Norvir-Free Boosted Prezista Tablet in the Works. Article dated June 28, 2011 from aidsmeds.com.

Tobira Starts Phase 2b Cenicriviroc Trial.  Article dated June 28, 2011 from hivandhepatitis.com.

Tobira Launches Phase II Study of Entry Inhibitor Cenicriviroc. Article dated June 24, 2011 from aidsmeds.com.

Turning to Stock-Market Math in Search of an HIV Cure. Article dated June 23, 2011 from aidsmeds.com.

HIV damages B-cells as well as T-cells: new treatment targets identified. Article dated June 10, 2011 from aidsmap.com.

Researchers Reverse HIV-Related B-Cell Exhaustion. Article dated June 7, 2011 from hivandhepatitis.com.

CROI 2011. See the section, “New gene therapy proves safe, effective.” Article dated May/June 2011 from Positively Aware.

CROI 2011. See the section, “New integrase inhibitor and Isentress resistance.” Article dated May/June 2011 from Positively Aware.

CROI 2011. See the section, “Prodrug of Viread more potent.” Article dated May/June 2011 from Positively Aware.

TBR-652 Inhibits HIV, May Dampen Inflammation.  Article dated May 31, 2011 from hivandhepatitis.com.

What Would You Do to Cure HIV?   Article dated May 25, 2011 from aidsmeds.com.

Study Finds Tobira’s New HIV Med TBR-652 Safe and Tolerable.  Article dated May 18, 2011 from aidsmeds.com.

Researchers Explore Agents that Reduce CD4 Cell Reservoir and Activate Latent HIV.  Article dated April 29, 2011 from hivandhepatitis.com.

Researchers Discover How TRIM5 Protects against HIV.  Article dated April 26, 2011 from hivandhepatitis.com.

Gold Drug Shows HIV Eradication Potential.  Article dated April 21, 2011 from aidsmeds.com.

Gold-based drug shows promise in clearing HIV reservoir in monkey study.  Article dated April 20, 2011 from aidsmap.com.

Gilead Quad Pill Works Better than AtriplaArticle dated April 5, 2011 from hivandhepatitis.com.

Apricitabine Gets a Second Chance.  Article dated April 5, 2011 from hivandhepatitis.com.

Gilead's Elvitegravir Showing Well in HIV Study.  Article dated March 23, 2011 from aidsmeds.com.

Could a Transmissible Treatment Help Curb HIV Epidemic?  Article dated March 22, 2011 from hivandhepatitis.com.

Experts Propose Transmissible Gene Therapy to Halt the HIV Epidemic.  Article dated March 18, 2011 from aidsmeds.com.

Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz.  Article dated March 18, 2011 from hivandhepatitis.com.

Transmissible gene therapy treatment proposed for HIV to curb epidemic.  Article dated March 17, 2011 from aidsmap.com.

Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV. Article dated March 15, 2011 from hivandhepatitis.com.

New Tenofovir Pro-drug GS-7340 Looks Good in Early Study. Article dated March 11, 2011 from hivandhepatitis.com.

CROI 2011: HIV Non-Nuke Rilpivirine Less Likely Than Sustiva to Cause Vitamin D Drops. Article dated March 8, 2011 from aidsmeds.com.

Twice-Daily Dolutegravir ("572") Holds Up in Heavily Raltegravir-Resistant Patients, Phase 2B Study Finds. Article dated March 7, 2011 from The Body Pro website.

No More Science Fiction: HIV Gene Therapy Delivers. Article dated March 4, 2011 from hivandhepatitis.com.

HIV Attachment Inhibitor BMS-663068 Shows Good Activity in Phase 2a Trial. Article dated March 4, 2011 from hivandhepatitis.com.

Promising New Gene Therapy for HIV Immunity. Article dated March 3, 2011 from CDC's HIV/Hepatitis/STD/TB Prevention News Update.

Early Monotherapy Results Look Good for BMS-663068, Potential First-in-Class Oral HIV Attachment Inhibitor. Article dated March 3, 2011 from The Body PRO website.

Zinc Fingers and Gene Therapies for HIV: Mimicking the Cured Berlin Patient?  Article dated March 2, 2011 from The Body Pro website.

CROI 2011: ViiV Integrase Inhibitor Dolutegravir Is Better Twice-Daily for Treatment-Experienced People. Article dated March 2, 2011 from aidsmeds.com.

CROI 2011: Encouraging Results for BMS s Oral HIV Attachment Inhibitor. Article dated March 1, 2011 from aidsmeds.com.

Attachment inhibitor BMS-663068 potent and well-tolerated in early study.  Article dated March 1, 2011 from aidsmap.com.

Gene Therapy Makes Small but Promising Early Steps Forward as Potential Form of HIV Treatment. Article dated March 1, 2011 from The Body Pro website.

Zinc finger gene therapy produces HIV-resistant CD4 T-cells. Article dated March 1, 2011 from aidsmap.com.

Could MicroRNA Be the Next Great Frontier in HIV/AIDS Treatment -- and Prevention? Article and video dated February 28, 2011 from The Body Pro website.

CROI 2011: CCR5 Gene Therapy Shows HIV Treatment Potential. Article dated February 28, 2011 from aidsmeds.com.

AIDS Activists Call on Public to Support New FDA HIV Drug Approval Policy. Article dated February 23, 2011 from aidsmeds.com.

Evaluation Resumes for Gilead's Rilpivirine/Truvada Single-tablet. Article dated February 18, 2011 from hivandhepatitis.com.

Gilead and Tibotec's Combo HIV Drug Is Back on Track. Article dated February 11, 2011 from aidsmeds.com.

FDA Puts a Hold on Development of ViiV HIV Drug. Article dated February 10, 2011 from aidsmeds.com.

Math Wizards Develop New HIV Drug Candidates. Article dated February 9, 2011 from aidsmeds.com.

Clinical Trial of Triple-Drug Combination Pill 572-Trial Begins. Article dated February 3, 2011 from aidsmeds.com.

Researchers Identify Novel HIV Replication Strategy in Macrophages. Article dated February 1, 2011 from hivandhepatitis.com.

Another three-in-one HIV pill. Article dated January/February 2011 from Positively Aware.

Research Reveals Complete Structure of HIV's Capsid Shell.  Article dated January 28, 2011 from hivandhepatitis.com.

FDA Declines New Drug Application for Rilpivirine/Truvada Combination Pill.  Article dated January 28, 2011 from hivandhepatitis.com.

Approval of Gilead and Tibotec's New Combo HIV Pill Hits Snag.  Article dated January 26, 2011 from aidsmeds.com. 

Discovery About HIV Could Lead to New Prevention and Treatment Approaches. Article dated January 25, 2011 from aidsmeds.com.

NIH Launches Center to Help Develop New Drugs. Article dated January 24, 2011 from aidsmeds.com.

Experimental Drug KP-1461 Steps Up HIV Mutation Rate. Article dated January 21, 2011 from hivandhepatitis.com.

RNA Interference Combination Strategy Shows Promise in Laboratory Study. Article dated January 14, 2011 from hivandhepatitis.com.

Bristol-Myers Squibb Acquires Experimental NRTI Festinavir. Article dated January 11, 2011 from hivandhepatitis.com.

Novel Entry Inhibitor VIR-576 Shows Promise in Early Study. Article dated January 7, 2011 from hivandhepatitis.com.

German Researchers Developing New HIV Fusion Inhibitor. Article dated December 30, 2010 from aidsmeds.com.

Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV. Article dated December 21, 2010 from aidsmap.com.

BMS Acquires New HIV Drug Festinavir. Article dated December 21, 2010 from aidsmeds.com.

Stem cell transplant has cured HIV infection in 'Berlin patient', say doctors. Article dated December 13, 2010 from aidsmap.com.

Berlin Patient Follow-Up 'Strongly Suggests' HIV Cure. Article dated December 10, 2010 from aidsmeds.com.

Briefly: New drug application for TMC278. Article from the November/December 2010 issue of Positively Aware.

The Buzz: Anticipation for a new single-tablet regimen based on rilpivirine (TMC278). Article from the November/December 2010 issue of Positively Aware.

ICAAC 2010. Article from the November/December 2010 issue of Positively Aware. See section called "TMC278, Atripla, and resistance."

ICAAC 2010. Article from the November/December 2010 issue of Positively Aware. See section called "Atripla rival gets good news."

ICAAC 2010. Article from the November/December 2010 issue of Positively Aware. See section called "Goodbye, Norvir—hello, cobicistat?"

Conference update: IAS/Vienna. Article from the November/December 2010 issue of Positively Aware. See section called "TBR-652 dual CCR5/CCR2 inhibitor study."

Gilead Submits Application for FDA Approval for a New Single-Pill HIV Regimen. Article dated November 24, 2010 from aidsmeds.com.

Protein Discovery Helps Explain the Body's Failure to Kill HIV. Article dated November 19, 2010 from aidsmeds.com.

New ViiV HIV Integrase Works Against Mild to Moderate Isentress-Resistant Virus. Article dated November 17, 2010 from aidsmeds.com.

Good Early Results for New ViiV HIV Integrase Inhibitor.  Article dated November 12, 2010 from aidsmeds.com.

Antinausea Drug Stops HIV Too.  Article dated November 10, 2010 from aidsmeds.com.

Anti-nausea drug has anti-HIV effect too.  Article dated November 4, 2010 from aidsmap.com.

HIV Antibodies Do Control Infection: New Hope for Vaccines and Treatment.  Article dated October 25, 2010 from aidsmeds.com.

Briefly: R.I.P., vicriviroc. Article from the September/October 2010 issue of Positively Aware.

One on One: Sharon Lewin discusses emerging strategies in cure research. Article from the September/October 2010 issue of Positively Aware.

International AIDS Conference: 572 integrase inhibitor. Article from the September/October 2010 issue of Positively Aware.

International AIDS Conference: 572 and drug resistance. Article from the September/October 2010 issue of Positively Aware.

International AIDS Conference: More good drug news: TMC278. Article from the September/October 2010 issue of Positively Aware.

Poor Adherence, High Viral Loads Help Explain Rilpivirine Treatment Failures. Article dated September 16, 2010 from aidsmeds.com.

Gilead's "Quad" HIV Medication Has Similar Efficacy to Atripla. Article dated September 13, 2010 from aidsmeds.com.

AIDS Cure Research: North Carolina Scientist Study Cancer Drug. Article dated September 3, 2010 from aidsmeds.com.

News briefs. See section called “Rilpivirine Shows Potent Activity” in this article from the Summer/Fall 2010 issue of BETA.

News briefs. See section called “TBR-652 Inhibits HIV, May Reduce Inflammation” in this article from the Summer/Fall 2010 issue of BETA.

News briefs. See section called “GSK-572 Integrase Inhibitor Shines in Phase II” in this article from the Summer/Fall 2010 issue of BETA.

Two Approved Cancer Drugs Fight HIV. Article dated August 23, 2010 from aidsmeds.com.

New Strategy Could Eradicate Latent HIV-Infected Cells. Article dated August 19, 2010 from aidsmeds.com.

Briefly. Truvada-TMC278 combo dose meets trial expectations. Article from the July/August 2010 issue of Positively Aware.

TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near. Article dated July 28, 2010 from thebody.com. 

Tibotec Submits Approval Application for HIV Non-Nuke Rilpivirine. Article dated July 26, 2010 from aidsmeds.com.

IAC 2010: More Details of TBR-652's Antiviral and Anti-Inflammatory Potential Reported. Article dated July 23, 2010 from aidsmeds.com.

Experimental integrase inhibitor GSK-572 shows continued promise. Article dated July 23, 2010 from aidsmap.com.

Rilpivirine (TMC278) matches efavirenz in phase 3 studies,with fewer side effects. Article dated July 22, 2010 from aidsmap.com.

TBR-652 blocks both CCR5 and CCR2, inhibiting HIV replication and reducing inflammation. Article dated July 21, 2010 from aidsmap.com.

New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains. Article dated July 20, 2010 from aidsmeds.com.

Argos's Dendritic Cell Therapy Reduces HIV During Treatment Interruption. Article dated July 19, 2010 from aidsmeds.com.

Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc. Article dated July 15, 2010 from aidsmeds.com.

Merck stops development of CCR5 inhibitor vicriviroc. Article dated July 15, 2010 from aidsmap.com.

Activist Group Claims HIV Cure Is Closer Than Many Think. Article dated July 14, 2010 from aidsmeds.com.

HIV Stem Cell Therapy in Mice Is Successful. Article dated July 7, 2010 from aidsmeds.com.

Pipeline Problems.  Article dated June 22, 2010 from aidsmeds.com.

Novel Anti-HIV Gene Therapy Demonstrates Glimmers of Success.  Article dated June 17, 2010 from aidsmeds.com.

Myriad halts HIV maturation inhibitor drug programme.  Article dated June 8, 2010 from aidsmap.com.

CROI treatment update. Article from the May/June 2010 issue of Positively Aware. See section called "New targets."

CROI treatment update. Article from the May/June 2010 issue of Positively Aware. See section called "CCR5 antagonists: TBR-652 and vicriviroc."

CROI treatment update. Article from the May/June 2010 issue of Positively Aware. See section called "New drugs will need new designs."

HIV Gene Therapy VRX496 & Vaccine Therapy: VIRxSYS Presents Results from Multiple Studies at the 13th ASGCT Annual Meeting.  Article dated May 24, 2010 from natap.org. 

New grants for HIV cure research. Article dated May 13, 2010 from aidsmap.com.

Avexa halts apricitabine development due to cash shortage. Article dated May 10, 2010 from aidsmap.com.

Avexa Shelves Development of HIV Drug Apricitabine. Article dated May 10, 2010 from aidsmeds.com.

New Single-Pill HIV Combo Moves Forward.   Article dated April 30, 2010 from aidsmeds.com. 

Rilpivirine Is Comparable to Sustiva for First-Time Treatment.  Article dated April 23, 2010 from aidsmeds.com.

Rilpivirine proves non-inferior to efavirenz in phase 3 studies. Article dated April 20, 2010 from aidsmap.com.


New Therapy Shows Potential as an Anti-HIV Medication. Article dated April 9, 2010 from aidsmeds.com.

Researchers Announce New HIV-Silencing Stem Cell Therapy. Article dated April 1, 2010 from aidsmeds.com.

Coming down the line.  Article from the March/April 2010 issue of Positively Aware.

European Researchers Patent Promising New HIV Compound.  Article dated March 25, 2010 from aidsmeds.com. 

Acne drug prevents HIV activation from latently infected cells.  Article dated March 24, 2010 from aidsmap.com. 

Acne Drug May Aid Antiretroviral Therapy for HIV.  Article dated March 23, 2010 from aidsmeds.com.  

No Benefit From Cyclosporine During Early Infection. Article dated March 18, 2010 from aidsmeds.com.

Chemical in Bananas May Prevent and Treat HIV. Article dated March 15, 2010 from aidsmeds.com.

CROI 2010: New Treatments for HIV: Part 1. Article dated March 9, 2010 from aidsmeds.com.

Abortion Pill for HIV Doesn’t Pan Out in Study. Article dated March 4, 2010 from aidsmeds.com.

News Briefs. See section called “Good Results for New Booster and Quad Pill” in this article from the Winter/Spring 2010 issue of BETA.

News Briefs. See section called “Vicriviroc Faces Further Challenges” in this article from the Winter/Spring 2010 issue of BETA.

Drug Watch: KP-1461:A Novel Anti-HIV Drug in Limbo?  Article from the Winter/Spring 2010 issue of BETA.

CCR5 antagonist vicriviroc fails to surpass potent background regimen. Article dated February 18, 2010 from aidsmap.com. 

New CCR5 antagonist TBR-652 shows good antiviral activity in early study. Article dated February 18, 2010 from aidsmap.com.

Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir. Article dated February 18, 2010 from aidsmap.com.

CROI 2010: Quad Pill and Boosting Drug Show Well in Studies. Article dated February 17, 2010 from aidsmeds.com.

Targeting Hidden HIV: Research Group Licenses New Prostratin Technology. Article dated February 8, 2010 from aidsmeds.com.

New Drug Fights HIV and Many Other Viruses. Article dated February 3, 2010 from aidsmeds.com.

Scientists Crack Integrase Inhibitor Mystery. Article dated February 1, 2010 from aidsmeds.com.

ICAAC Update. Article from the January/February 2010 issue of Positively Aware. See section called "New drug in the works: GSK-744."

ICAAC Update. Article from the January/February 2010 issue of Positively Aware. See section called "Another new drug in the works: PRO 140."

ICAAC Update. Article from the January/February 2010 issue of Positively Aware. See section called "In further development: vicriviroc."

ICAAC Update. Article from the January/February 2010 issue of Positively Aware. See section called "Yet another new drug in the works: MPC–4326."

Long-Lasting HIV Nucleoside Analogue in Development. Article dated January 28, 2010 from aidsmeds.com.

No Approval (Yet) for Merck s HIV Drug Vicriviroc. Article dated January 21, 2010 from aidsmeds.com.

Merck will not seek vicriviroc licenses in treatment-experienced. Article dated January 21, 2010 from aidsmap.com.

Gilead Reports Success With Quad Pill and Boosting Drug. Article dated January 6, 2010 from aidsmeds.com.  

Body Might Eliminate Best Weapon Against HIV. Article dated December 17, 2009 from aidsmeds.com. 

Researchers Engineer HIV-Killing Cells From Stem Cells. Article dated December 8, 2009 from aidsmeds.com. 

Gene-Based Drug Fights Hep C in Chimps Maybe HIV One Day. Article dated December 4, 2009 from aidsmeds.com.

PI Resistance Reduces Bevirimat Potency. Article dated November 20, 2009 from aidsmeds.com.

Highlights from the 2009 International AIDS Society Conference.  See the section, "GSK/Shionogi’s integrase inhibitor 572 - The New Kid on the Block."  News brief from the November 2009 issue of Positively Aware.   

Discovery of enzyme structure points way to creating less toxic anti-HIV drugs.  Article dated October 16, 2009 from aidsmap.com. 

Progress in Finding a New Class of HIV Drugs.  Article dated October 14, 2009 from aidsmeds.com.

Avexa Closes Phase III Trial of HIV Drug Apricitabine.  Article dated October 5, 2009 from aidsmeds.com. 

New Gilead Drug As Good As Norvir for Boosting Reyataz.  Article dated September 21, 2009 from aidsmeds.com. 

Maturation inhibitor bevirimat is well tolerated and effective in predicted responders.  Article dated September 18, 2009 from aidsmap.com. 

GSK's second integrase inhibitor looks potent and well-tolerated in early study.  Article dated September 17, 2009 from aidsmap.com. 

ICAAC: Single-Dose PRO 140 Reduces HIV Levels for at least 10 Days.  Article dated September 15, 2009 from aidsmeds.com. 

A New Simpler Gene Therapy for HIV.  Article dated September 3, 2009 from aidsmeds.com.

Researchers identify promising agents for HIV cure research.  Article dated September 2, 2009 from aidsmap.com.

Drug Watch: Two new pharmacoenhancers give HAART a boost.  Article from the Summer/Fall 2009 issue of BETA

 

New Synthetic Proteins Block HIV.  Article dated August 18, 2009 from aidsmeds.com.

Peering in the Pipeline.  Article from the Summer 2009 issue of Achieve.  Also available in Spanish as a PDF file (see pages 20 to 21 of this issue).

CROI round-up: New information on the heart, plus a possible alternative to Norvir and more.   Article dated May 2009 from Positively Aware.  

Drug Watch: Nanotechnology for Antiretroviral Drug Delivery.  Article from the Winter/Spring 2009 issue of BETA.   

HIV Drugs in the Pipeline: A concise summary of drugs further along in development.  Article dated March 2009 from Positively Aware

Treatment round-up from the International AIDS Conference: New and improved drug information. Article dated November 2008 from Positively Aware.  This article includes sections on several different new and experimental drugs.

Comparing two integrase inhibitors: The first head-to-head study comparing raltegravir and elvitegravir.  Article dated September 2008 from Positively Aware

Antiretroviral therapy roundup from CROI [2008]: Report on newer drugs in development and some already approved drugs.  Article dated May 2008 from Positively Aware

News briefs:  New drug targets.  Article dated March 2008 from Positively Aware.

IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated. Article dated July 26, 2011 from hivandhepatitis.com. - experimental, integrase

 

IAS 2011: Raltegravir Still Effective at 5 Years. Article dated July 26, 2011 from hivandhepatitis.com. - integrase

 

IAS 2011: Doubt Remains if HIV Therapy Increases the Risk of Fragility Fractures. Article dated July 26, 2011 from hivandhepatitis.com. - bone

 

IAS 2011: PrEP Effective for Heterosexuals, Discordant Couples. Article dated July 26, 2011 from hivandhepatitis.com. - serodiscordant, heterosexuals, PrEP, prevention

 

Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation. Article dated July 26, 2011 from hivandhepatitis.com. - HBV

 

IAS 2011: Boceprevir Response Differs According to HCV Genotype 1 Subtype. Article dated July 26, 2011 from hivandhepatitis.com. - HCV

 

PSI-7977 plus Standard Therapy Cures 100% of Genotype 2-3 Hepatitis C Patients. Article dated July 26, 2011 from hivandhepatitis.com. - HCV

 

Herpes drugs and viral load: valaciclovir works better than aciclovir. Article dated July 26, 2011 from aidsmap.com. - herpes, viral load, STD

 

Valaciclovir slows HIV disease progression in pregnant and breastfeeding women. Article dated July 26, 2011 from aidsmap.com. - herpes, STD, pregnancy, transmission

 

High levels of unmet need for family planning in people with HIV - couples unaware of conception and contraception options. Article dated July 26, 2011 from aidsmap.com. - pregnancy, family planning

 

IAS 2011: Hearing Loss Tied to Age, Gender, Race; Not HIV. Article dated July 26, 2011 from aidsmeds.com. - aging, deaf

 

IAS 2011: Norvir-Boosted Reyataz Comparable in HIV-Positive Women Versus Men. Article dated July 25, 2011 from aidsmeds.com. - women

 

Infant prophylaxis during breastfeeding reduces risk of HIV infection by 71%. Article dated July 25, 2011 from aidsmap.com. - children

 

What's next for HIV prevention? Paying people to be healthy. Article dated July 25, 2011 from aidsmap.com. - prevention

 

Another NRTI-sparing regimen does well in treatment-naive patients. Article dated July 25, 2011 from aidsmap.com. - TX innovative

 

Gay men’s PrEP study final results: near 90% efficacy in men who took drug, but adherence even lower than thought. Article dated July 22, 2011 from aidsmap.com. - PrEP, MSM, adherence, transgender, prevention

 

HIV vaccine technologists edge nearer to effective designs. Article dated July 22, 2011 from aidsmap.com. - vaccine

 

IAS 2011: PrEP in iPrEx: 92% Fewer Infections in Those With Detectable Drug Levels. Article dated July 22, 2011 from aidsmeds.com. - MSM, transgender, PrEP, prevention

 

IAS 2011: Hormone-Based Birth Control Raises HIV Risk. Article dated July 21, 2011 from aidsmeds.com. - transmission, pregnancy – family planning

 

IAS 2011: Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies. Article dated July 21, 2011 from aidsmeds.com. - TX comparisons

 

IAS 2011: Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients. Article dated July 21, 2011 from aidsmeds.com. - HCV

 

IAS 2011: Five-Year Follow-Up: Isentress Comparable to Sustiva. Article dated July 21, 2011 from aidsmeds.com. - TX comparisons

 

IAS 2011: VIRxSYS Vaccine 'Functionally' Cures Two Monkeys in Recent Study. Article dated July 21, 2011 from aidsmeds.com. - vaccine, cure

 

Hepatitis C Sexually Transmitted between HIV-Positive Men. Article dated July 21, 2011 from aidsmeds.com. - HCV, MSM

 

IAS 2011: New Jersey: Emergency Room HIV Testing Works. Article dated July 21, 2011 from aidsmeds.com. - testing

 

All active news articles